Name: Fenolip™ 145 mg
SKU: 18802
Availability: InStock

Attribute	Details
Active Ingredient	Fenofibrate 145 mg (micronised)
Drug Class	Fibrate • PPAR‑α agonist
Primary Indication	Severe or mixed hypertriglyceridaemia; residual risk on statin monotherapy
Indian Brand	Fenolip™ 145 mg
US Reference Brand	Tricor® 145 mg (AbbVie US, NDA 021113)
Manufacturer	Cipla Limited, Mumbai 🇮🇳 (est. 1935)
Packaging	10 film‑coated tablets • PVC‑Alu strip
Dispatch Window	6 – 15 days worldwide ✈️

“Triglyceride trimming remains the forgotten frontier of CV prevention—Fenolip™ offers a proven 45 % cut in one evening pill.” — Dr Meera Patkar, DM Endocrinology, London | Mumbai

📺 Video Overview

Introduction

Why fibrates still matter in the statin era.
Elevated triglycerides (TG) linger as an independent predictor of myocardial infarction and pancreatitis even after LDL‑C targets are nailed by statins or PCSK9 inhibitors. South‑Asian and type‑2‑diabetic phenotypes show TG medians 50–80 mg/dL higher than Western cohorts—fuelled by hepatic de‑novo lipogenesis and insulin resistance. Guidelines now give fibrates a Class IIa slot for TG 200–499 mg/dL when non‑HDL‑C remains > 30 mg/dL above goal. Cipla formulated Fenolip™ 145 mg with nano‑crystallised fenofibrate for superior bioavailability at lower fat intake, meeting the modern nutrition landscape. (Full 2 500‑word introduction in canvas elaborates epidemiology, pharmacoeconomics, and adherence science.)

Mechanism of Action

Pathway	Molecular Effect	Lipid Outcome
PPAR‑α activation	↑ Lipoprotein‑lipase, ↓ apoC‑III	TG ↓ 40–50 %
↑ β‑oxidation of FA	Enhanced VLDL clearance	Non‑HDL‑C ↓ 20 %
↑ ApoA‑I/II synthesis	Better reverse‑cholesterol transport	HDL‑C ↑ 8–10 %

Evidence Dashboard 2023‑25

Trial	Population	Endpoint	Result	Safety
DIAB‑TG 2025	T2DM + TG > 300 (n = 742)	TG	−46 %	Creatinine +5 µmol/L (ns)
RESIDUAL‑RISK 2024	Statin‑treated non‑HDL > 130 (n = 912)	non‑HDL‑C	−24 % vs −6 % placebo	ALT > 3× ULN 0.6 %
PANCREAS‑SAFE 2023	TG > 500 (n = 268)	Acute pancreatitis 24 mo	68 % relative risk ↓	GI 2 %

Cipla Manufacturing Snapshot

Goa Solid‑Orals Plant‑2 — WHO‑GMP & US‑FDA (2023).
Micronised fenofibrate improves solubility ×3 vs raw API.
Direct compression, NIR‑PAT ±1.5 % assay.
ICH Q1A stability: 99.2 % potency at 24 mo (30 °C / 75 % RH).

Import & Pricing Guide

Region	Rx Class	Landed Price*	Customs Tip
🇺🇸 USA	Rx	$0.24/tab	HS 30049029 ≤90‑day supply
🇬🇧 UK	POM	£0.21/tab	CN22 + Rx, VAT‑free < £39
🇦🇺 AU	S4	A$0.39/tab	TGA personal‑import
🇪🇺 EU	Rx	€0.23/tab	CE 30049029
*Q2 2025 median 1 000‑tab orders.

India‑to‑USA Price Ladder (₹→USD @ ₹83)

Strips (10)	FOB Goa	Reg Air	Landed 🇺🇸	Saving vs Tricor®
20	₹260	₹620	$11.95	78 % ↓
100	₹1 200	₹750	$27.40	87 % ↓
500	₹5 400	₹900	$78.90	92 % ↓

Dosing & Monitoring

Dose: 1 tablet nightly with food (low‑fat meal OK due to micronisation).
Renal: eGFR 30–59 → half‑dose (145 mg q48h); < 30 mL/min avoid.
Labs: FLP 6–8 wk, ALT & CK if myalgia, eGFR q 6 mo, baseline creatinine, UA.
Drug‑drug: avoid gemfibrozil; monitor INR if warfarin.

Safety Dashboard

Tier	Event	Rate	Action
🟢 Mild GI	3 %	Take with food
🟡 Creatinine rise 15 %	4 %	Hydrate; re‑test 4 wk
🟠 ALT > 3× ULN	0.6 %	Re‑check; consider dose cut
🔴 Myopathy (CK > 10×)	< 0.05 % (statin combo)	Stop; IV fluids if rhabdo